1. Home
  2. HHS vs NEUP Comparison

HHS vs NEUP Comparison

Compare HHS & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harte-Hanks Inc.

HHS

Harte-Hanks Inc.

N/A

Current Price

$4.52

Market Cap

17.7M

ML Signal

N/A

Logo Neuphoria Therapeutics Inc.

NEUP

Neuphoria Therapeutics Inc.

N/A

Current Price

$3.51

Market Cap

20.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
HHS
NEUP
Founded
1923
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
17.7M
20.6M
IPO Year
1994
2002

Fundamental Metrics

Financial Performance
Metric
HHS
NEUP
Price
$4.52
$3.51
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 94.9K
15.0K
Earning Date
11-09-2026
09-18-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 97.35
N/A
EPS
★ N/A
N/A
Revenue
★ $159,570,000.00
$1,174,165.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$2.00
$3.19
52 Week High
$4.67
$21.31

Technical Indicators

Market Signals
Indicator
HHS
NEUP
Relative Strength Index (RSI) 65.97 30.87
Support Level $4.14 $3.28
Resistance Level N/A $3.86
Average True Range (ATR) 0.09 0.08
MACD -0.05 -0.01
Stochastic Oscillator 74.42 9.68

Price Performance

Historical Comparison
HHS
NEUP

About HHS Harte-Hanks Inc.

Harte-Hanks Inc is a customer experience company. The company operates three business segments: Revenue Solutions; Customer Care; and Fulfillment & Logistics Services. It derives maximum revenue from Fulfillment & Logistics Services segment. The Fulfillment & Logistics Services segment includes printing, lettershop, advanced mail optimization (including commingling services), logistics and transportation optimization, monitoring and tracking, to support traditional and specialized mailings. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: